Comparison
Armodafinil vs Semax
Side-by-side of Armodafinil and Semax. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Armodafinil
Armodafinil is the R-enantiomer sold as Nuvigil. Half-life 10-15 h, 150 mg standard dose, narcolepsy and shift-work approvals, Schedule IV.
Semax
Semax peptide benefits: nootropic ACTH(4-10) analog without corticotropic activity. Cognitive enhancement, neuroprotection, intranasal dosing, Russian stroke.
Effects at a glance
Armodafinil
- •FDA approved in 2007 for narcolepsy, shift-work sleep disorder, and OSA residual sleepiness
- •R-enantiomer of modafinil; 150 mg armodafinil is roughly equivalent to 200 mg modafinil
- •Schedule IV controlled in the US; prescription-only globally
- •Longer terminal half-life of about 15 hours produces extended late-day wakefulness coverage
- •Same CYP3A4 induction as modafinil; reduces hormonal contraceptive efficacy
- •Side-effect profile and dermatologic risk warnings mirror modafinil
Semax
- •Synthetic heptapeptide analog of ACTH(4-10) developed in Russia in the 1980s
- •Approved in Russia for ischemic stroke, cognitive impairment, and cerebrovascular disorders
- •Lacks the corticotropic activity of native ACTH due to the Pro-Gly-Pro stabilizing tail
- •Russian RCTs report improved cognitive recovery in acute ischemic stroke versus standard care
- •Modulates BDNF and NGF expression and dopaminergic signaling in preclinical models
- •Standard route is intranasal; not FDA approved; research-use-only outside Russia
Side-by-side
| Attribute | Armodafinil | Semax |
|---|---|---|
| Category | pharmaceutical | peptide |
| Also known as | Nuvigil, R-modafinil, (R)-(-)-modafinil | Met-Glu-His-Phe-Pro-Gly-Pro, ACTH(4-10) Pro-Gly-Pro analog |
| Half-life (hr) ↗ | 15 | 0.5 |
| Typical dose (mg) ↗ | 150 | 0.6 |
| Dosing frequency | daily, morning | 2-3x daily (intranasal) |
| Routes | oral | intranasal |
| Onset (hr) | 1 | 0.5 |
| Peak (hr) | 3 | 2 |
| Molecular weight | 273.35 | 813.94 |
| Molecular formula | C15H15NO2S | C37H51N9O10S |
| Mechanism | Weak dopamine reuptake inhibition plus downstream activation of histaminergic, noradrenergic, and orexinergic wake systems; R-enantiomer of modafinil with longer half-life. | Modulates BDNF and NGF expression in hippocampus and cortex, enhances dopaminergic and serotonergic signaling, and reduces oxidative stress markers in preclinical ischemia models. Lacks corticotropic activity of native ACTH. |
| Legal status | Schedule IV (US); prescription-only globally; not a supplement | Approved in Russia for stroke and cognitive disorders; not FDA approved; research-use-only grey market elsewhere |
| WADA status | banned | unknown |
| DEA / Rx | Schedule IV | Not FDA approved; not scheduled; research-chemical status outside Russia |
| Pregnancy | Not recommended | Not recommended; insufficient data |
| CAS | 112111-43-0 | 80714-61-0 |
| PubChem CID | 9148206 | 9811102 |
| Wikidata | Q4791953 | Q4413083 |
Safety profile
Armodafinil
Common side effects
- headache
- nausea
- dizziness
- anxiety
- insomnia (with later-day dosing)
- dry mouth
- mild blood pressure elevation
Contraindications
- recent myocardial infarction
- unstable angina
- left ventricular hypertrophy
- significant arrhythmia
- history of Stevens-Johnson syndrome
- psychotic disorders
- pregnancy
- concurrent MAOI use
Interactions
- hormonal contraceptives: CYP3A4 induction reduces contraceptive efficacy; use barrier method(major)
- cyclosporine: reduced cyclosporine levels via CYP3A4 induction(major)
- warfarin: CYP2C9 inhibition raises INR(moderate)
- phenytoin: CYP2C19 inhibition raises phenytoin levels(moderate)
- MAOIs: potential hypertensive reaction(major)
- classical stimulants: additive cardiovascular and sleep-disruption effects(moderate)
Semax
Common side effects
- mild nasal irritation
- transient mild headache
- rare mild euphoria or activation
Contraindications
- pregnancy
- lactation
- acute psychotic disorder
- severe hypertension (caution due to mild activating effect)
Interactions
- stimulants (caffeine, amphetamines): potential additive activation; monitor for overstimulation(minor)
- antipsychotics: theoretical antagonism via dopaminergic modulation(minor)
Which Should You Take?
Armodafinil comes out ahead for most readers on the criteria we weight: 3 catalogued goals, controlled substance, oral dosing, with a Tier-A outcome catalogued. Semax is the right call when one of the conditionals below applies.
- → If your priority is wakefulness, pick Armodafinil.
- → If your priority is fatigue resistance, pick Armodafinil.
- → If your priority is long-term neuroprotection, pick Semax.
- → If your priority is stroke recovery, pick Semax.
Edge case: Half-lives differ materially (Armodafinil ~15 hr vs Semax ~0.5 hr). Armodafinil reaches steady state faster; Semax is easier to dial in if tolerability is uncertain.
Default choice: Armodafinil. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Semax only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Armodafinil and Semax?
Armodafinil and Semax differ in category (pharmaceutical vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Armodafinil or Semax?
Armodafinil half-life is 15 hours; Semax half-life is 0.5 hours.
Can you stack Armodafinil with Semax?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper